Key result
A decrease in the eGFRcystatin C/eGFRcreatinine-ratio was associated with a progressive increase in mortality after elective cardiac surgery, with risk increasing as the ratio dropped from 1.0 to 0.90.
Why the study?
No systematic studies had evaluated variation in the eGFRcystatin C/eGFRcreatinine-ratio used for shrunken pore syndrome diagnosis, nor whether early and midterm mortality after elective cardiac surgery varies with this ratio.
Does the preoperative eGFRcystatin C/eGFRcreatinine-ratio correlate with early and midterm mortality following elective cardiac surgery?
Population
4007 patients undergoing elective CABG and/or sAVR
Comparison
Variation in preoperative eGFRcystatin C/eGFRcreatinine-ratio
Follow-up
Mean follow-up time was 3.6 years
Authors
Loading...
May refine postoperative mortality prediction; hypothesis-generating and requires prospective validation before clinical use.
Cohort (n=4,007)
Does the preoperative eGFRcystatin C/eGFRcreatinine-ratio correlate with early and midterm mortality following elective cardiac surgery?
A lower preoperative eGFRcystatin C/eGFRcreatinine-ratio is progressively associated with increased 1- and 3-year all-cause mortality in patients undergoing elective cardiac surgery.
Herou et al. (2019) conducted a cohort in Elective cardiac surgery (CABG and/or sAVR) (n=4,007). Decreased eGFRcystatin C/eGFRcreatinine-ratio (Shrunken pore syndrome) vs. Higher eGFRcystatin C/eGFRcreatinine-ratio (e.g., 1.0) was evaluated on All-cause mortality. A decrease in the eGFRcystatin C/eGFRcreatinine-ratio was associated with a progressive increase in mortality after elective cardiac surgery, with risk increasing as the ratio dropped from 1.0 to 0.90.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: